Our research projects are funded by the following federal agencies:

K01  Improved methods to assess the comparative safety of new psychiatric medications, 2013-2018, NIMH
​R01 Comparative safety of commonly prescribed psychotropic drugs in pregnant women, 2014-2017, NIMH

R03 Ondansetron and risk of congenital malformations, 2017-2019, NICHD
K08 Comparative safety and effectiveness of antihypertensives in pregnancy, 2013-2018, NICHD
​R21 Pregnancy registries nested in the international pooled health care databases, 2017-2019, NICHD

R01 The impact of prescription opioid use on pregnancy outcomes, 2017-2021, NIDA

R01 Comparative effectiveness and safety of depression treatments during pregnancy, 2009-2014, AHRQ

Developing the capability of using national Medicaid data for FDA post-marketing surveillance to assess medication safety during pregnancy, 2017-2019, FDA

We also conduct research sponsored by industry partners (e.g., Eli Lilly, GlaxoSmithKline).